Bicycle Therapeutics Limited (NASDAQ:BCYC) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 188,200 shares, a growth of 22.0% from the August 31st total of 154,300 shares. Currently, 1.3% of the shares of the company are short sold. Based on an average trading volume of 74,300 shares, the short-interest ratio is presently 2.5 days.
In related news, major shareholder Plc Glaxosmithkline sold 1,597 shares of the company’s stock in a transaction dated Tuesday, July 14th. The shares were sold at an average price of $19.27, for a total value of $30,774.19. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 26.30% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its holdings in shares of Bicycle